Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cinromide in epilepsy: a pilot study.

A J Wilensky, L M Ojemann, P N Friel

    Epilepsia
    |August 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The amplitude and origin of sea-level variability during the Pliocene epoch.

    Nature·2019
    Same author

    The multi-millennial Antarctic commitment to future sea-level rise.

    Nature·2015
    Same author

    Antarctic contribution to meltwater pulse 1A from reduced Southern Ocean overturning.

    Nature communications·2014
    Same author

    Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

    Neurology·2012
    Same author

    Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

    Clinical pharmacology and therapeutics·2010
    Same author

    Pharmacological and clinical aspects of antiepileptic drug use in the elderly.

    Epilepsy research·2005
    Same journal

    Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

    Epilepsia·2026
    Same journal

    Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

    Epilepsia·2026
    Same journal

    Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

    Epilepsia·2026
    Same journal

    Long-term mortality after status epilepticus: A 5-year analysis study.

    Epilepsia·2026
    Same journal

    The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

    Epilepsia·2026
    Same journal

    Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

    Epilepsia·2026
    See all related articles

    Cinromide, an experimental antiepileptic drug, showed limited clinical usefulness for partial epilepsy. Patients experienced worse seizure control and potential cognitive decline, leading to its withdrawal from testing.

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Epilepsy is a neurological disorder characterized by recurrent seizures.
    • Partial epilepsy involves seizures originating in one area of the brain.
    • Antiepileptic drugs (AEDs) are used to manage seizure disorders.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of cinromide as monotherapy in adult outpatients with uncontrolled partial epilepsy.
    • To compare cinromide with established AEDs like phenytoin and carbamazepine.

    Main Methods:

    • A crossover study design involving 11 adult outpatients with uncontrolled partial epilepsy.
    • Patients received phenytoin (2 months), cinromide (4 months), and carbamazepine (4 months) sequentially.
    • Seizure control, toxicity, and neuropsychological performance were assessed.

    Related Experiment Videos

    Main Results:

    • Four patients withdrew during or after switching to cinromide due to increased seizure activity.
    • Overall seizure control was comparable across the three drugs, but cinromide was associated with the worst control of secondarily generalized seizures.
    • Neuropsychological test performance tended to decrease during cinromide treatment.
    • Central nervous system and gastrointestinal toxicities were common initially with cinromide but often subsided.
    • No laboratory abnormalities necessitated drug withdrawal.

    Conclusions:

    • Cinromide demonstrated very limited clinical utility for partial epilepsy.
    • The drug was associated with poorer seizure control and potential cognitive impairment.
    • Based on these findings, cinromide has been withdrawn from further development by its manufacturer.